Bidani A, Tzouanakis A E, Cardenas V J, Zwischenberger J B
Department of Internal Medicine, University of Texas Medical Branch, Galveston 77555-0561.
JAMA. 1994 Sep 28;272(12):957-62.
To evaluate the potential efficacy of pressure limitation with permissive hypercapnia in the treatment of acute respiratory failure/adult respiratory distress syndrome on the basis of current theories of ventilator-induced lung injury, potential complications of systemic hypercarbia, and available human outcome studies.
Articles were identified through MEDLINE, reference citations of published data, and consultation with authorities in their respective fields.
Animal model experimentation and human clinical trials were selected on the basis of whether they addressed the questions of pressure limitation with or without hypercapnia, the pathophysiologic effects of hypercapnia, or the concept of ventilator-induced parenchymal lung injury. Frequently cited references were preferentially included.
Data were analyzed with particular emphasis on obtaining the following variables from the clinical studies: peak inspiratory pressures, tidal volumes, minute ventilation, and PCO2. Quantitative aspects of respiratory physiology were used to analyze the theoretical effects of permissive hypercapnia on ventilatory requirements in normal and injured lungs.
Extensive animal model data support the hypothesis that ventilator-driven alveolar overdistention can induce significant parenchymal lung injury. The heterogeneous nature of lung injury in adult respiratory distress syndrome, with its small physiologic lung volume, may render the lung susceptible to this type of injury through the use of conventional tidal volumes (10 to 15 mL/kg). Permissive hypercapnia is an approach whereby alveolar overdistention is minimized through either pressure or volume limitation, and the potential deleterious consequences of respiratory acidosis are accepted. Uncontrolled human trials of explicit or implicit permissive hypercapnia have demonstrated improved survival in comparison with models of predictive mortality.
Avoidance of alveolar overdistention through pressure or volume limitation has significant support based on animal models and computer simulation. Deleterious effects of the associated hypercarbia in severe lung injury do not appear to be a significant limiting factor in preliminary human clinical trials. Although current uncontrolled studies suggest benefit, controlled trials are urgently needed to confirm these findings before adoption of the treatment can be endorsed.
基于目前关于呼吸机所致肺损伤的理论、系统性高碳酸血症的潜在并发症以及现有的人体研究结果,评估允许性高碳酸血症的压力限制在治疗急性呼吸衰竭/成人呼吸窘迫综合征中的潜在疗效。
通过医学文献数据库(MEDLINE)、已发表数据的参考文献以及与各领域权威专家咨询来确定相关文章。
根据动物模型实验和人体临床试验是否涉及有或无高碳酸血症的压力限制问题、高碳酸血症的病理生理效应或呼吸机所致实质性肺损伤的概念来进行选择。优先纳入被频繁引用的参考文献。
对资料进行分析时,特别着重从临床研究中获取以下变量:吸气峰压、潮气量、分钟通气量和二氧化碳分压。运用呼吸生理学的定量方法来分析允许性高碳酸血症对正常及损伤肺通气需求的理论效应。
大量动物模型数据支持这样的假说,即呼吸机驱动的肺泡过度扩张可导致显著的实质性肺损伤。成人呼吸窘迫综合征中肺损伤具有异质性,且生理肺容积较小,通过使用传统潮气量(10至15毫升/千克)可能使肺易受此类损伤。允许性高碳酸血症是一种通过压力或容量限制将肺泡过度扩张降至最低,并接受呼吸性酸中毒潜在有害后果的方法。明确或隐含的允许性高碳酸血症的非对照人体试验表明,与预测死亡率模型相比,生存率有所提高。
基于动物模型和计算机模拟,通过压力或容量限制避免肺泡过度扩张有充分依据。在初步人体临床试验中,严重肺损伤相关高碳酸血症的有害效应似乎并非显著限制因素。尽管目前的非对照研究提示有益,但在认可采用该治疗方法之前,迫切需要进行对照试验以证实这些发现。